Biovail Rx Products Spur Revenue Growth, Fuisz Acquisition Expands Pipeline
This article was originally published in The Tan Sheet
Executive Summary
While Biovail's branded and generic Rx products spurred second quarter and first half revenue and income growth, the $154 mil. acquisition of Fuisz Technologies and its drug delivery systems will give the Canadian pharmaceutical company an opening into the OTC, nutraceutical and food ingredient markets.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning